Diabetes Mellitus Clinical Trial
Official title:
Acute Insulin Effects on Cardiac Function in Patients With Diabetes Mellitus
Our investigation studies the role of acute insulin administration on the diabetic heart,
its corresponding effective blood-insulin level and the time-course applicability of insulin
in a routine clinical setting.
A case series of six male (48.1 ± 4.9 y/o) patients with controlled diabetes (HbA1c of 6.6 ±
0.3%, disease duration of 14.4 ± 6.7 yr). Each subject was evaluated for glucose
homeostatic, hemodynamic and echocardiographic systolic and diastolic parameters at baseline
and following two successive insulin-load steps of a euglycemic hyperinsulinemic clamp
study, each 2 h in duration. Results are presented as a mean ± SEM and analysed using the
student's t-test.
Patients:
Six male diabetic (five type 2 and one type 1) patients, 30-65 year old, with an established
diagnosis of diabetes mellitus for ≥2 years, who were free of significant valvular heart
disease, atrial arrhythmia or cardiac pacing comprised the study population. Patients'
characteristics are summarized in table 1.
Each patient served as his or her own control. The study protocol was approved by the ethics
committee at Rambam Medical Center, Haifa, Israel. Prior to the study, patients gave written
informed consent after receiving a detailed explanation as to the purpose of the study, the
technique, its side effects and the study protocol.
Patients were studied within a clinical research facility at the Rambam Medical Center,
Haifa, Israel. Baseline evaluation was conducted at 8:00 am after 12 h of fasting, followed
by two hyperinsulinemic euglycemic clamp (EHC) steps (2 h each step); The following vital
signs were monitored during the study protocol: manual heart rate, systolic blood pressure
(SBP), diastolic blood pressure (DBP) and baseline 12-lead electrocardiogram (ECG)
recording. Glucose consumption rates against changing insulin levels were measured by the
EHC technique. Cardiac function parameters were measured in the last 10 min of each step by
tissue Doppler echocardiography. Results are presented as a mean ± SEM.
Clamp technique:
Each patient underwent an EHC study according to the protocol described previously, and
implemented in our institute. Baseline measurements of blood insulin and glucose levels were
collected. Thereafter, two insulin loads were initiated. The blood glucose level was kept
near euglycemia (90 ± 5 mg/dl) throughout 2 h period of each insulin load step. Intravenous
(iv) insulin loads were administered by 1- and 10-mU/kg·min at steps 1 and 2 of insulin
loading (Lispro Insulin, Eli Lilly, France), respectively. Dexstrose in water 50% (DW50) was
infused at variable infusion rates, titrated to maintain euglycemia. Concomitant saline
0.45% was used to dilute the DW50 in order to prevent hypertonicity-induced irritation of
the cannuled vein. During the baseline period, saline 0.45% infusion rates were 0.75 ml/min
to keep the iv cannule open. Every patient was given a chance to urinate before step 2.
Glucose and insulin homeostatic parameters of the study group were compared to those of
healthy controls we studied earlier.
Cardiac function assessment:
Transthoracic echocardiography was performed by a qualified echocardiographer using a
General Electric Vivid 3 machine (Tirat HaCarmel, Israel). Parameters were assessed as the
mean of three consecutive heart beats.
Systolic echocardiographic parameters:
LV fractional shortening (LVFS) derived from end diastolic and end systolic LV dimensions;
LV ejection fraction (LVEF) derived from end diastolic and end systolic LV volumes.
Diastolic echocardiographic parameters:
1. Mitral valve diastolic flow parameters by pulse wave Doppler: E wave, represents early
diastolic filling; A wave, represents late diastolic filling concomitant with the
atrial kick, E/A ratio and E wave deceleration time (DT).
2. Tissue Doppler-derived velocities of the mitral annulus: E' represents early diastolic
velocity synchronous to the mitral inflow E wave, measured close to the
interventricular septum (E' medial) and lateral wall (E' lateral); E' mean, derived
from E' lateral and E' medial. A' represents late diastolic velocity to the synchronous
mitral inflow A wave, measured close to the septum (A' medial) and lateral wall (A'
lateral). A' mean is derived from A' lat. and A' med. A' reflects mitral annulus
movement during atrial contraction. The E to E' ratio represents diastolic LV
compliance.
Results are presented as mean ± SEM and analyzed using the student's t-test. Statistical
significance considered when p value less than 0.05.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |